Expiration date: 04/2025

The composition and form of issue:

Suspension for injection 1 vial contains:

hydrocortisone acetate 125 mg

lidocaine hydrochloride 25 mg

excipients: methyl parahydroxybenzoate parahydroxybenzoate sodium chloride sodium phosphate sodium dihydrogen phosphate povidone Polysorbate 80 N,N-dimethylacetamide water for injections 

in vials of 5 ml in a cardboard pack 1 bottle.

Description pharmaceutical form:

White or almost white suspension with a characteristic odor.

Method of application and dose:

Intra - and periarticular,/m. Re-introduction is possible with the 3-week interval. The injection directly into the joint can have an adverse effect on hyaline cartilage, therefore, the same joint can be treated with no more than 3 times a year.

When tendinite injection should be into the vagina of the tendon (directly into the tendon can not enter). The drug is not used for systemic treatment and for the treatment of the Achilles tendon.

Adults: intra - and periarticular — 5-50 mg, depending on the size of joint and severity of the disease.

V/m adults impose deep in the gluteus muscle at a dose of 125-250 mg per day.

Children: 5-30 mg/day, divided into several doses. A single dose periarticular injection: children aged from 3 months to 1 year 25 mg, from 1 year to 6 years — 25-50 mg, 6-14 years — 50-75 mg.

In elderly patients the risk of adverse reactions above.

The purpose of the drug in the first trimester of pregnancy is contraindicated due to the lack of sufficient data on the safe application, at a later date is possible only after careful weighing of benefit and risk (the likelihood of the formation of cleft palate and intrauterine development disorders small).

Use during lactation can lead to the violation of adrenal function and development of infants because of corticosteroids and lidocaine penetrate into breast milk.

Storage conditions:

In the original packaging.